Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 53 articles: HTML format

Single Articles

November 2025
1. NISAR M, Awan AR, Ahmad A, Saleem H, et al
   Diagnostic accuracy of anti-integrin alphavbeta6 in ulcerative colitis: a diagnostic meta-analysis.
   J Gastroenterol. 2025 Nov 13. doi: 10.1007/s00535-025-02319.
   PubMed     Abstract available
   
   
   
2. YOSHIDA A, Takagi T, Kawashima K, Moriya K, et al
   Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.
   J Gastroenterol. 2025 Nov 7. doi: 10.1007/s00535-025-02313.
   PubMed     Abstract available
   
   
   
3. MAUDUIT A, Mas E, Sola-Tapias N, Menard S, et al
   Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.
   J Gastroenterol. 2025;60:1323-1338.
   PubMed     Abstract available
   
   
   September 2025
4. SONG H, Zhou Y, Liu S, Zhang Q, et al
   Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome: the cross-sectional and longitudinal relationship.
   J Gastroenterol. 2025 Sep 28. doi: 10.1007/s00535-025-02304.
   PubMed     Abstract available
   
   
   
5. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
   Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
   J Gastroenterol. 2025 Sep 22. doi: 10.1007/s00535-025-02299.
   PubMed     Abstract available
   
   
   
6. TSUTSUI A, Murakami Y, Nishiwaki Y, Asakura K, et al
   Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.
   J Gastroenterol. 2025 Sep 2. doi: 10.1007/s00535-025-02295.
   PubMed     Abstract available
   
   
   July 2025
7. AKIYAMA S, Ito Y, Shiroyama M, Suzuki S, et al
   Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I?BRITE cohort study.
   J Gastroenterol. 2025 Jul 8. doi: 10.1007/s00535-025-02279.
   PubMed     Abstract available
   
   
   
8. ZAKERSKA-BANASZAK O, Ladziak K, Kruszka D, Maciejewski K, et al
   New potential biomarkers of ulcerative colitis and disease course - integrated metagenomic and metabolomic analysis among Polish patients.
   J Gastroenterol. 2025 Jul 4. doi: 10.1007/s00535-025-02280.
   PubMed     Abstract available
   
   
   
9. KUDO T, Arai K, Iwama I, Hagiwara SI, et al
   Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan.
   J Gastroenterol. 2025 Jul 2. doi: 10.1007/s00535-025-02271.
   PubMed     Abstract available
   
   
   
10. MORI R, Ogino T, Murakami M, Kayama H, et al
    Group 1 innate lymphoid cells and inflammatory macrophages exacerbate fibrosis in creeping fat through IFN-gamma secretion.
    J Gastroenterol. 2025;60:838-853.
    PubMed     Abstract available
    
    
    May 2025
11. SAWAHASHI M, Kakuta Y, Naito T, Okazaki S, et al
    Autoantibodies against endothelial protein C receptor and integrin alphavbeta6 predict the development of ulcerative colitis.
    J Gastroenterol. 2025 May 15. doi: 10.1007/s00535-025-02263.
    PubMed     Abstract available
    
    
    
12. JUN YK, Choi Y, Shin CM, Park YS, et al
    Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02244.
    PubMed     Abstract available
    
    
    April 2025
13. MATSUOKA K, Motoya S, Yamamoto T, Matsuura M, et al
    Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.
    J Gastroenterol. 2025 Apr 21. doi: 10.1007/s00535-025-02249.
    PubMed     Abstract available
    
    
    
14. UENO N, Sakatani A, Ando K, Saito S, et al
    Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.
    J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02248.
    PubMed     Abstract available
    
    
    March 2025
15. OGINO Y, Sadashima K, Yoshida Y, Takedomi H, et al
    Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02235.
    PubMed     Abstract available
    
    
    
16. AKIYAMA S, Hayashi R, Takasago T, Kusunoki K, et al
    Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.
    J Gastroenterol. 2025 Mar 6. doi: 10.1007/s00535-025-02231.
    PubMed     Abstract available
    
    
    
17. OKABAYASHI S, Itaya T, Yamazaki H, Yanai R, et al
    Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors.
    J Gastroenterol. 2025;60:285-293.
    PubMed     Abstract available
    
    
    February 2025
18. KIM MK, Shin SH, Lee CH, Kim S, et al
    Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease.
    J Gastroenterol. 2025 Feb 26. doi: 10.1007/s00535-025-02230.
    PubMed     Abstract available
    
    
    
19. OKITA M, Takenaka K, Hirai F, Ashizuka S, et al
    Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel.
    J Gastroenterol. 2025 Feb 14. doi: 10.1007/s00535-025-02223.
    PubMed     Abstract available
    
    
    January 2025
20. NAGANUMA M, Shiga H, Shimoda M, Matsuura M, et al
    First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
    J Gastroenterol. 2025 Jan 30. doi: 10.1007/s00535-025-02216.
    PubMed     Abstract available
    
    
    December 2024
21. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Publisher Correction: Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203.
    PubMed    
    
    
    
22. NAGANUMA M
    Reply to "Severe ulcerative colitis: diagnostic criteria and therapy".
    J Gastroenterol. 2024 Dec 14. doi: 10.1007/s00535-024-02200.
    PubMed    
    
    
    
23. NISHIOKA K, Ogino H, Ihara E, Chinen T, et al
    Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse.
    J Gastroenterol. 2024 Dec 13. doi: 10.1007/s00535-024-02199.
    PubMed     Abstract available
    
    
    
24. CHIBA M
    Severe ulcerative colitis: diagnostic criteria and therapy.
    J Gastroenterol. 2024 Dec 11. doi: 10.1007/s00535-024-02198.
    PubMed    
    
    
    
25. XIONG Z, Li X, Xie M, Guo J, et al
    Small extracellular vesicles derived from adipose mesenchymal stem cells alleviate intestinal fibrosis by inhibiting the FAK/Akt signaling pathway via MFGE8.
    J Gastroenterol. 2024;59:1092-1106.
    PubMed     Abstract available
    
    
    November 2024
26. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Nov 28. doi: 10.1007/s00535-024-02176.
    PubMed     Abstract available
    
    
    
27. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    PubMed     Abstract available
    
    
    
28. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis.
    J Gastroenterol. 2024 Nov 11. doi: 10.1007/s00535-024-02172.
    PubMed     Abstract available
    
    
    September 2024
29. CHEN G, Wu X, Zhu H, Li K, et al
    Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases.
    J Gastroenterol. 2024 Sep 10. doi: 10.1007/s00535-024-02148.
    PubMed     Abstract available
    
    
    July 2024
30. MASSIRONI S, Furfaro F, Bencardino S, Allocca M, et al
    Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.
    J Gastroenterol. 2024 Jul 9. doi: 10.1007/s00535-024-02130.
    PubMed     Abstract available
    
    
    June 2024
31. TAKAHASHI K, Morita N, Tamano R, Gao P, et al
    Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    J Gastroenterol. 2024 Jun 14. doi: 10.1007/s00535-024-02121.
    PubMed     Abstract available
    
    
    May 2024
32. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2024 May 30. doi: 10.1007/s00535-024-02116.
    PubMed    
    
    
    
33. NAGANUMA M
    Reply to "promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy".
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02113.
    PubMed    
    
    
    
34. CHIBA M, Kimura K
    Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.
    J Gastroenterol. 2024 May 4. doi: 10.1007/s00535-024-02111.
    PubMed    
    
    
    
35. IMAZU N, Torisu T, Yokote A, Umeno J, et al
    Arginase 2 attenuates ulcerative colitis by antioxidant effects of spermidine.
    J Gastroenterol. 2024 May 2. doi: 10.1007/s00535-024-02104.
    PubMed     Abstract available
    
    
    April 2024
36. MAKUUCHI M, Kakuta Y, Umeno J, Fujii T, et al
    Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2024 Apr 8. doi: 10.1007/s00535-024-02099.
    PubMed     Abstract available
    
    
    March 2024
37. HIRAYAMA D, Hyodo S, Morita K, Nakase H, et al
    Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    J Gastroenterol. 2024 Mar 16. doi: 10.1007/s00535-024-02086.
    PubMed     Abstract available
    
    
    January 2024
38. NAGANUMA M, Nakamura N, Kunisaki R, Matsuoka K, et al
    Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
    J Gastroenterol. 2024 Jan 26. doi: 10.1007/s00535-024-02079.
    PubMed     Abstract available
    
    
    
39. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion.
    J Gastroenterol. 2024 Jan 21. doi: 10.1007/s00535-024-02077.
    PubMed     Abstract available
    
    
    November 2023
40. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Reply to "Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis".
    J Gastroenterol. 2023 Nov 27. doi: 10.1007/s00535-023-02064.
    PubMed    
    
    
    
41. SUN S, Lv B
    The antiferroptotic effect of indigo on ulcerative colitis.
    J Gastroenterol. 2023 Nov 23. doi: 10.1007/s00535-023-02063.
    PubMed     Abstract available
    
    
    October 2023
42. NAGANUMA M, Kobayashi T, Kunisaki R, Matsuoka K, et al
    Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02048.
    PubMed     Abstract available
    
    
    August 2023
43. WATANABE K, Nojima M, Nakase H, Sato T, et al
    Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
    J Gastroenterol. 2023 Aug 10. doi: 10.1007/s00535-023-02029.
    PubMed     Abstract available
    
    
    July 2023
44. PARKES G, Ungaro RC, Danese S, Abreu MT, et al
    Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    J Gastroenterol. 2023 Jul 25. doi: 10.1007/s00535-023-02013.
    PubMed     Abstract available
    
    
    
45. SAKURAI T, Omori T, Tanaka H, Ito T, et al
    Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn's disease in Japan (SPREAD-J study).
    J Gastroenterol. 2023 Jul 21. doi: 10.1007/s00535-023-02017.
    PubMed     Abstract available
    
    
    
46. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.
    J Gastroenterol. 2023 Jul 6. doi: 10.1007/s00535-023-02016.
    PubMed     Abstract available
    
    
    June 2023
47. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2023 Jun 23. doi: 10.1007/s00535-023-02005.
    PubMed     Abstract available
    
    
    
48. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    PubMed     Abstract available
    
    
    
49. SHINZAKI S, Sato T, Fukui H
    Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.
    J Gastroenterol. 2023;58:598-599.
    PubMed    
    
    
    May 2023
50. MATSUOKA K, Fujii T, Okamoto R, Yamada A, et al
    Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
    J Gastroenterol. 2023 May 5. doi: 10.1007/s00535-023-01998.
    PubMed    
    
    
    April 2023
51. WATANABE S, Ogasawara N, Kobayashi S, Kirino S, et al
    Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment.
    J Gastroenterol. 2023;58:379-393.
    PubMed     Abstract available
    
    
    March 2023
52. YAMAKAWA T, Kitamoto H, Nojima M, Kazama T, et al
    Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01979.
    PubMed    
    
    
    
53. NAMBU R, Arai K, Kudo T, Murakoshi T, et al
    Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01972.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.